MFDS Decision Speeds Up Review of Mifegyne Introduction

The Ministry of Food and Drug Safety has set a goal of introducing abortion medication by the first quarter of next year as it pushes to bring the drug into the formal regulatory system. In this process, the direction not to require additional trials involving Korean participants, which had been a key issue, has come into focus. The decision appears to reflect a judgment to expedite the domestic approval process based on usage experience already accumulated across a wide range of races and countries.

This judgment is in line with a recent regulatory stance that places less importance on additional domestic clinical trials when global usage data are considered sufficient. However, because this is a drug with high social sensitivity, a decision to speed up approval does not automatically put safety controversies to rest, making the design of post-marketing oversight and distribution control more important.

Strengthening Trust in Clinical Review and Procedures

Regarding allegations of external pressure surrounding a COVID-19 treatment candidate, MFDS working-level officials testified in court that there had been no pressure to rush the review and no omission of procedures. At the same time, the fact that the case was supplemented and then approved on October 26, just 33 days later shows that, apart from political controversy, the clinical review system is in practice heavily influenced by the completeness of the actual data and the manner in which they are submitted.

The issue is not simply whether preferential treatment occurred, but how much to reduce the possibility that poor-quality or distorted data could enter the review process. In that sense, the MFDS move to revise clinical guidelines for seven indications in the digital therapeutics field, and its statement that it will review policy improvements following the Genencell case, can be read as an effort to manage both approval speed and confidence in the review process at the same time.

Detailed Reorganization of Pharmacopeia and Quality Standards

In discussions by the Central Pharmaceutical Affairs Council, the testing methods for five essential national medicines and identification tests for 23 newly designated herbal medicinal materials were revised together. This suggests that, as concern has grown that customary management alone is insufficient for items whose supply is important or whose field-level identification is unstable, policy is moving toward establishing more detailed official testing standards.

Behind these changes is the reality of repeated violations in manufacturing and quality control. As on-site discrepancies became evident to the point that some companies were caught up to 12 times over five years, the MFDS has been reinforcing an approach that presents detailed dosage-form-specific standards, such as the quality guidelines for topical ophthalmic drugs, in order to manage development from the earliest stage through post-approval production using the same regulatory language.

Stronger Market Surveillance After Approval

Because consumer protection cannot be completed simply by revising approvals and standards, oversight at the distribution stage is also being strengthened. In a case involving false or exaggerated advertising for albumin products categorized as general foods, sales reached 518 million won, showing how products outside the formal system can quickly expand the market by stimulating expectations of health benefits.

Ultimately, the core of the recent trend is not simply to delay the entry of new products unconditionally. Taken together, the waiver of additional clinical trials, guideline revisions, new testing methods, and advertising crackdowns indicate that the MFDS is shifting its regulatory center of gravity toward introducing products more quickly while demanding more detailed post-market verification and stronger accountability for quality.